Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Anatomage Inc.Redefining the Limits of 3D Medical Study: Anatomage Expands Into Clinical Obesity and More Interactive PhysiologyAnatomage Inc., a market leader in medical visualization and education technology, is introducing its latest Anatomage Table platform update, with new obesity reference bodies, more real-human-based physiology simulations, and interactive...
- Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
- TempraMed Technologies Ltd.TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial FootprintTempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor" or "OGM") for the...
- SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier StudySciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that a new study will be initiated in a collaboration between NIH (National Institute of Health, US) and the Swiss...
- Evotec SEEvotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardWill lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovation Brings more than 25 years of global experience in pharma, biotechnology and academia HAMBURG, Germany, Oct. 15, 2026...
- The Rosen Law Firm PAHIMS DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
- Jeff Social MarketingDaily Home Magazine Launches New Online Publication for Homeowners and Everyday LivingDaily Home Magazine has launched a new online publication featuring articles and informational content covering real estate, construction, health, lifestyle, news and other topics related to everyday living.Image Caption: Daily Home Magazine launches a new online publication offering readers practical information and insights on homeownership and everyday living.To view an enhanced version of this graphic, please...
- Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class ActionThe complaint alleges that HIMS shared consumers' sensitive health information with advertising platforms and engaged in deceptive billing practices.
- Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their RightsRobbins LLP is investigating whether UNCY failed to properly inspect its third-party vendor's manufacturing facility per FDA requirements.
- Opella: New study demonstrates successful cough treatment extends beyond symptom reliefA new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional...
- Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPhase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an...
- Compass TherapeuticsCompass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).